About
3000 seats per session
01h00
English
Join Servier's Educationalwebinar on Type 2 Diabetes Management: " glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management"
This session we will explore strategies for managing Type 2 Diabetes Mellitus (T2DM) by examining the current knowledge on the central role of glucose control in the hierarchy of priorities.
Session will be presented by:
· Professor K. Khunti from UK
· Professor J. Chan from Hong-Kong
· Doctor V. Mohan from India
What can you expect from today’s session?
We will dive into the key challenges and considerations in managing T2DM, with a particular focus on the management priorities. The webinar will review the key role of glycemic control and the benefit of early glycemic control and the new finding. The impact on clinical practice will be highlighted.
If you attend 50% of the live broadcast, you'll receive a certificate of attendance
What you will learn
Highlight the central role of glycemic control in T2DM management
Overcome therapeutic inertia to reduce microvascular complications
Highlight organ-protective strategies alongside glucose control
Speakers
Program
-
Is glucose control still central in the hierarchy of priorities in type 2 management?
Prof. Kamlesh Khunti
o Landmark trials in type 2 diabetes explored the effects of intensive glucose control on diabetes-related outcomes and mortality
o Benefits of early glycaemic control
o These cardiovascular outcome trials (CVOTs) showed beneficial cardiorenal effects in people with type 2 diabetes at (very) high CV risk
o What the guidelines are recommending
o CVD complications in people with T2DM has improved but microvascular complications are worse
o Therapeutic inertia one of the major reasons for long delays in glucose control that is driving this high risk of microvascular complications
-
2. Importance of multifactorial management for long term benefits
Prof. Juliana Chan
o Legacy effect of early multifactorial treatment on CV-renal events and survival (RCT and RWE)
o High cost and poor QoL with complications
o Majority of patients on CVOT treated with multiple GLDs, statins and RASi
o Dual importance of organ protection and glucose lowering
o Early A1c intensification delays treatment escalation
o Pill burden, non-adherence and fixed dose combination
-
3. How might this impact on clinical practice in the foreseeable future?
Dr. Viswanathan Mohan
o Glucose control remains central and should be complemented by evidence-based, organ-protection strategies for the personalised management of type 2 diabetes
o Even in the trials showing beneficial effects of SGLT2s and GLP1 Ras. Glucose control still played a part
o ADVANCE -intensive glucose control paper
o Modern sulfonylureas like the extended release gliclazide and glimepiride are not only the most powerful of antidiabetic drugs, but are also cardiac safe
Audience
This event is for specialists below
Endocrinology - Diabetology - Medical Nutritionist
General Medicine
Internal Medicine
Cardiology and vascular disease
Contact us
Chat with us
- Chat available in the bottom left corner
Free